These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Study on protective effects and its mechanism of leflunomide on renal tissue in rat IgA nephropathy model].
    Author: Tang Y, Lou TQ, Wang C, Peng H, Liu X, Tang H.
    Journal: Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2008 May; 20(5):283-5. PubMed ID: 18471359.
    Abstract:
    OBJECTIVE: To observe the effects of leflunomide on renal pathology and expression of transforming growth factor-beta1 (TGF-beta1), monocyte chemotaxis peptide 1 (MCP-1) in renal tissue of experimental IgA nephropathy in rat. METHODS: IgA nephropathy model was reproduced in rats. They were randomly divided into leflunomide group, prednisone group, nephropathy control group, and normal control group. The deposition of immunocomplex in renal tissue and degree of mesangial matrix hyperplasia in mesangial region were detected by immunofluorescence and light microscope; the level of expression of gene and protein of TGF-beta1 and MCP-1 in renal tissue were determined by immunohistochemistry and reverse transcription-polymerase chain reaction (RT-PCR) methods. RESULTS: Compared with model group, leflunomide lessened the deposit of immunocomplex in renal tissue, alleviated the hyperplasia of mesangial matrix (all P<0.01). Leflunomide could also inhibit the expression of TGF-beta1, MCP-1 at the level of gene and protein in renal tissue (P<0.05 or P<0.01). CONCLUSION: Leflunomide can decrease the deposit of immunocomplex, down regulate the expression of TGF-beta1, MCP-1 in kidney, diminish local inflammatory reaction, relieve hyperplasia of mesangial matrix, related the process of nephrotic fibrosis, and protect renal function.
    [Abstract] [Full Text] [Related] [New Search]